Fluoxetine 40mg Tablets

Fluoxetine 40mg Tablets, also available as capsules, are a prescription-only generic equivalent of Prozac® 40mg, containing fluoxetine hydrochloride equivalent to fluoxetine 40mg per unit. Fluoxetine belongs to the selective serotonin reuptake inhibitor (SSRI) class of antidepressants. The 40mg strength represents a mid-to-higher dose, typically used when patients have not achieved an adequate therapeutic response at the standard 20mg maintenance dose, or as a dose step toward 60mg for conditions such as OCD or bulimia nervosa. Generic fluoxetine 40mg tablets and capsules are marketed internationally across the USA, UK, Australia, UAE, Germany, France, Russia, South Korea and worldwide under multiple brand and generic names.

[INTERNAL LINK: /fluoxetine-10mg-tablets/ "Fluoxetine 10mg Tablets"] [INTERNAL LINK: /fluoxetine-20mg-tablets/ "Fluoxetine 20mg Tablets"] [INTERNAL LINK: /fluoxetine-60mg-tablets/ "Fluoxetine 60mg Tablets"]

Product Information

Generic Manufacturers — Fluoxetine 40mg

Generic fluoxetine 40mg is manufactured by a range of pharmaceutical companies globally:

• Teva Pharmaceuticals (USA, UK, EU)
• Sandoz / Novartis (USA, UK, EU, AU)
• Mylan / Viatris (USA, UK, EU)
• Aurobindo Pharma (USA, UK, EU)
• Dr. Reddy's Laboratories (USA, UK, EU)
• Accord Healthcare (UK, EU)
• Hikma Pharmaceuticals (USA, UK)
• Sun Pharmaceutical (USA, UK, EU)

Pack sizes, dosage form (tablet vs capsule), excipients and market availability vary by manufacturer. The 40mg strength may be less widely stocked than the 20mg and should be confirmed with your pharmacy or supplier.

Fluoxetine 40mg is prescribed for the following conditions where the standard 20mg dose has not produced a sufficient therapeutic response, subject to market-specific approved labeling:

Major Depressive Disorder (MDD) — Inadequate Response at 20mg When a patient has not responded adequately to fluoxetine 20mg after 4–8 weeks of treatment, the dose may be increased to 40mg once daily under medical supervision. Fluoxetine 40mg is used as a mid-range dose in treatment-escalation protocols for depression.

Obsessive-Compulsive Disorder (OCD) For OCD, fluoxetine doses of 40–60mg per day are commonly required for adequate symptom control. Fluoxetine 40mg is a key dose step in OCD titration, both as a standalone dose and as a step toward 60mg where approved. OCD often requires higher doses and longer treatment duration than depression.

Panic Disorder In some patients with panic disorder, doses above 20mg are required. Fluoxetine 40mg may be used where 20mg provides inadequate control of panic attacks or anticipatory anxiety.

Bulimia Nervosa — Dose Titration The approved dose for bulimia nervosa is fluoxetine 60mg/day. Fluoxetine 40mg represents a titration step toward this target dose, allowing gradual dose escalation under clinical supervision.

Treatment-Resistant Depression In patients with treatment-resistant or refractory depression, higher fluoxetine doses including 40mg and 60mg are explored before switching or augmenting therapy.

United States: Fluoxetine 40mg is available as capsules and tablets from multiple FDA-approved generic manufacturers. Commonly used for OCD, treatment-resistant depression and as a titration step for bulimia nervosa (target: 60mg). The product carries an FDA Black Box Warning for increased suicidal thinking and behaviour in children, adolescents and young adults during early treatment.

United Kingdom / EU: Fluoxetine 40mg is used in the UK as a dose escalation option for depression, OCD and bulimia nervosa per MHRA/EMA-approved labeling and BNF guidance. Available from multiple MHRA-approved generic manufacturers. PIL and SPC are available for all authorised products.

Australia: Fluoxetine 40mg Australia products are listed on the Australian Register of Therapeutic Goods (ARTG). PBS subsidisation applies subject to indication and patient eligibility. Consult your prescriber regarding PBS authority requirements for higher-dose fluoxetine.

UAE / Gulf: Fluoxetine 40mg is available in the UAE through MOHAP-registered pharmacies on prescription. Availability of the specific 40mg strength varies by registered product and emirate. Prescription-only (POM) in all GCC states.

Germany: Fluoxetin 40mg is available in Germany as tablets and capsules. Prescription-only (rezeptpflichtig). Used in depression and OCD where standard doses are insufficient. All products carry German-language Beipackzettel (package inserts).

France: Fluoxétine 40mg is available as tablets and capsules in France under multiple generic names, subject to ANSM approval, prescription and reimbursement conditions.

Russia: Флуоксетин 40 мг is available in Russia under multiple brand and generic names on valid prescription. Oversight by the Ministry of Health of the Russian Federation.

South Korea: 플루옥세틴 40mg is registered for prescription use in South Korea per MFDS-approved labeling. Used for depression and OCD dose titration.

Always follow the prescribing information for your country and the guidance of your licensed healthcare professional.

Dose decisions must always be made by a licensed prescriber. Do not self-adjust fluoxetine doses.

Black Box Warning (USA): Antidepressants including fluoxetine may increase the risk of suicidal thoughts and behaviours in children, adolescents and young adults (up to age 24) during early treatment. Risk monitoring is particularly important during dose increases. Monitor all patients for worsening depression, suicidality, agitation and unusual behavioural changes.

Dose Escalation Caution: Increasing fluoxetine from 20mg to 40mg should be done gradually and under medical supervision. Higher doses carry a greater risk of side effects including insomnia, agitation, tremor, sexual dysfunction and serotonin-related adverse effects.

Serotonin Syndrome: Risk increases with higher doses and concurrent serotonergic medications. Symptoms include agitation, confusion, rapid heart rate, high blood pressure, dilated pupils, muscle twitching and hyperthermia. Seek immediate medical attention if suspected.

CYP450 Interactions: Fluoxetine is a potent CYP2D6 inhibitor. Higher doses intensify this inhibitory effect. Significant interactions with codeine (reduced efficacy), tamoxifen (reduced efficacy), tricyclics, antipsychotics and antiarrhythmics. Full medication review essential.

Long Half-Life: Fluoxetine and its active metabolite norfluoxetine have a combined half-life of 1–4 weeks. Dose changes take weeks to reach new steady state. Do not rush titration.

Pregnancy & Breastfeeding: Category C (USA). Neonatal adaptation syndrome reported with third-trimester SSRI exposure. Fluoxetine is excreted in breast milk. Risk-benefit assessment required. Consult prescriber.

Supply, pack size and formulation vary by manufacturer and country. This information is for reference only and does not constitute medical advice.